Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition.
Akyüz F, An YK, Begun J, Aniwan S, Bui HH, Chan W, Choi CH, Chopdat N, Connor SJ, Desai D, Flanagan E, Kobayashi T, Lai AY, Leong RW, Leow AH, Leung WK, Limsrivilai J, Muzellina VN, Peddi K, Ran Z, Wei SC, Sollano J, Teo MMH, Wu K, Ye BD, Ooi CJ. Akyüz F, et al. Among authors: begun j. Intest Res. 2024 Nov 4. doi: 10.5217/ir.2024.00089. Online ahead of print. Intest Res. 2024. PMID: 39492666 Review.
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement.
Lu C, Rosentreter R, Parker CE, Remillard J, Wilson SR, Baker ME, Bhatnagar G, Begun J, Bruining DH, Bryant RV, Christensen B, Feagan BG, Fletcher JG, Gordon I, Henderson G, Jairath V, Knudsen J, Kucharzik T, Lesack K, Maaser C, Maconi G, Novak K, Rimola J, Taylor SA, Wilkens R, Rieder F; Stenosis Therapy and Anti-Fibrotic Research (STAR) consortium. Lu C, et al. Among authors: begun j. Lancet Gastroenterol Hepatol. 2024 Oct 21:S2468-1253(24)00265-6. doi: 10.1016/S2468-1253(24)00265-6. Online ahead of print. Lancet Gastroenterol Hepatol. 2024. PMID: 39447590
Group B Streptococcus vaginal colonisation throughout pregnancy is associated with decreased Lactobacillus crispatus and increased Lactobacillus iners abundance in the vaginal microbial community.
Maidment TI, Pelzer ES, Borg DJ, Cheung E, Begun J, Nitert MD, Rae KM, Clifton VL, Carey AJ. Maidment TI, et al. Among authors: begun j. Front Cell Infect Microbiol. 2024 Sep 30;14:1435745. doi: 10.3389/fcimb.2024.1435745. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 39403199 Free PMC article.
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective.
Parigi TL, Solitano V, Armuzzi A, Barreiro de Acosta M, Begun J, Ben-Horin S, Biedermann L, Colombel JF, Dignass A, Fumery M, Ghosh S, Kobayashi T, Louis E, Magro F, Panaccione R, Rausch A, Reinisch W, Selinger C, Jairath V, Danese S, Peyrin-Biroulet L. Parigi TL, et al. Among authors: begun j. United European Gastroenterol J. 2024 Oct 5. doi: 10.1002/ueg2.12671. Online ahead of print. United European Gastroenterol J. 2024. PMID: 39367753 Free article. Review.
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.
Sands BE, Feagan BG, Peyrin-Biroulet L, Danese S, Rubin DT, Laurent O, Luo A, Nguyen DD, Lu J, Yen M, Leszczyszyn J, Kempiński R, McGovern DPB, Ma C, Ritter TE, Targan S; ARTEMIS-UC Study Group. Sands BE, et al. N Engl J Med. 2024 Sep 26;391(12):1119-1129. doi: 10.1056/NEJMoa2314076. N Engl J Med. 2024. PMID: 39321363 Clinical Trial.
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial.
Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, Rosella O, Proud D, Brouwer R, Gorelik A, Liew D, Connell WR, Wright EK, Taylor KM, Pudipeddi A, Sawers M, Christensen B, Ng W, Begun J, Radford-Smith G, Garg M, Martin N, van Langenberg DR, Ding NS, Beswick L, Leong RW, Sparrow MP, De Cruz P. Choy MC, et al. Among authors: begun j. Lancet Gastroenterol Hepatol. 2024 Nov;9(11):981-996. doi: 10.1016/S2468-1253(24)00200-0. Epub 2024 Sep 2. Lancet Gastroenterol Hepatol. 2024. PMID: 39236736 Clinical Trial.
Reliability of Intestinal Ultrasound for Evaluating Crohn's Disease Activity Using Point-of-care and Central Reading.
Goodsall TM, An YK, Andrews JM, Begun J, Friedman AB, Lee A, Lewindon PJ, Spizzo P, Rodgers N, Taylor KM, White LS, Wilkens R, Wright EK, Zou L, Maguire BR, Parker CE, Rémillard J, Novak KL, Panaccione R, Feagan BG, Jairath V, Ma C, Bryant RV. Goodsall TM, et al. Among authors: begun j. Clin Gastroenterol Hepatol. 2024 Aug 28:S1542-3565(24)00773-0. doi: 10.1016/j.cgh.2024.08.007. Online ahead of print. Clin Gastroenterol Hepatol. 2024. PMID: 39209200
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
201 results